Today: 21 May 2026
Browse Category

NYSE:MRK 4 February 2026 - 12 May 2026

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

Dow Jones Today: Why the Blue-Chip Rally Stalled as Apple, S&P 500 and Nasdaq Pushed Higher

The Dow Jones Industrial Average fell 78.72 points to 49,573.42 by midday Friday, reversing an early rally as tariff concerns weighed on gains from Apple and other strong earnings reports. President Donald Trump announced a 25% tariff on EU-made cars and trucks starting next week. Apple reported quarterly revenue of $111.2 billion, up 17% year over year. Oil prices dropped after Iran sent a new negotiation proposal.
1 May 2026
·····
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

Schwab’s U.S. Dividend Equity ETF (SCHD) increased health care holdings to 18.5% in its annual rebalance, adding Abbott Laboratories and UnitedHealth Group near the top at about 3.8% each. SCHD attracted $4 billion in Q1 as U.S. dividend funds pulled in $24.1 billion, the highest first-quarter inflow in four years. SCHD closed at $30.48 Monday, up 0.13%.
30 March 2026
············
Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals shares traded at $52.86 in U.S. premarket Thursday, just below Merck’s $53-per-share cash offer after Merck agreed to acquire the company for about $6.7 billion. The deal centers on Terns’ leukemia drug TERN-701, which showed a 75% major molecular response rate in early trials. The offer requires over 50% of shares tendered and antitrust approval. Terns would owe Merck $235 million if it accepts a higher bid.
26 March 2026
···
Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck will acquire Terns Pharmaceuticals for $53 per share in cash, valuing the company at about $6.7 billion. The deal gives Merck rights to TERN-701, an experimental leukemia drug, as it prepares for Keytruda’s patent expirations in 2028. The offer represents a 6% premium to Terns’ last close and is subject to antitrust review and shareholder approval. Merck expects to close the transaction in the second quarter.
25 March 2026
··
Merck stock: weekend Keytruda-Welireg data and Gardasil cuts set up Monday trade

Merck stock: weekend Keytruda-Welireg data and Gardasil cuts set up Monday trade

Merck shares closed up 3.8% at $123.82 Friday after reporting new cancer trial results for Keytruda and Welireg, with an FDA decision on the combination set for June 19, 2026. The company also announced about 150 job cuts at a North Carolina Gardasil vaccine plant amid weaker demand. Merck highlighted positive data in kidney, bladder, and ovarian cancer studies. Shares were little changed after hours.
28 February 2026
··
Merck stock price hits a 52-week high on Deutsche Bank upgrade as MRK heads into holiday week

Merck stock price hits a 52-week high on Deutsche Bank upgrade as MRK heads into holiday week

Merck shares rose 1.8% to $121.41 Friday after Deutsche Bank upgraded the stock and raised its price target to $150. The stock hit a 52-week high of $123.33 before markets closed for the Presidents Day holiday. Merck plans to present new bladder and kidney cancer data at the ASCO GU meeting later this month. Chief marketing officer Chirfi Guindo sold 10,000 shares earlier in the week, according to a regulatory filing.
15 February 2026
··
Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck shares climbed 1.8% to $121.41 in after-hours trading Friday after Deutsche Bank upgraded the stock and raised its price target. The move comes ahead of key cancer study results set for release at the ASCO Genitourinary Cancers Symposium later this month. Merck’s chief marketing officer sold 10,000 shares on Feb. 12. U.S. markets are closed Monday for Washington’s Birthday; trading resumes Tuesday.
13 February 2026
··
Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck shares fell 0.5% to $117.01 after SEC filings showed insider stock sales by two executives on Feb. 9. Chief Marketing Officer Chirfi Guindo sold 10,000 shares; Executive Vice President Jennifer Zachary exercised and sold 121,573 shares. The moves followed a revenue forecast below Wall Street estimates. Merck underperformed the broader market and sector peers.
10 February 2026
··
Dow Jones futures tick up as Wall Street braces for retail sales, jobs and CPI

Dow Jones futures tick up as Wall Street braces for retail sales, jobs and CPI

Dow futures rose 45 points to 50,264 early Tuesday after the index closed at a record 50,135.87 on Monday. Investors await U.S. retail sales data at 8:30 a.m. ET, with forecasts at 0.4%, followed by key payroll and inflation reports later this week. Tech stocks led Monday’s rebound, while losses in Amgen and Merck weighed on the Dow. Earnings from major consumer and industrial firms are also due.
10 February 2026
··
Merck stock slides 3.5% as insider sale filing lands; traders eye next FDA deadline

Merck stock slides 3.5% as insider sale filing lands; traders eye next FDA deadline

Merck & Co shares dropped 3.5% to $117.65 Monday, underperforming a tech-led market rebound. EVP Jennifer Zachary sold 121,573 shares at a weighted-average $119.15 after exercising options, according to an SEC filing. The FDA is expected to rule Feb. 20 on expanding Keytruda’s use for ovarian cancer. Merck remains reliant on Keytruda as older drugs face increased competition.
10 February 2026
·
Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen shares dropped 1.8% to $377.28 in mid-afternoon trading Monday, weighing on the Dow Jones Industrial Average. The decline followed news of an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% fall in Enbrel sales last quarter. Broader drug stocks lagged while traders awaited key U.S. jobs and inflation data later in the week.
9 February 2026
····
Merck stock drops nearly 4%: why MRK is lagging the market today

Merck stock drops nearly 4%: why MRK is lagging the market today

Merck shares fell 3.9% to $117.16 Monday, underperforming the broader market as investors weighed patent risks and 2026 earnings guidance. Amgen, Pfizer, and AbbVie also declined. Merck last week projected 2026 sales of up to $67 billion and warned of a $2.5 billion hit from generic competition and weaker COVID-19 drug sales. The Dow lagged as Merck and Amgen dragged on the index.
9 February 2026
··
Dow Jones Industrial Average slips under 50,000 as AI shakeout bites; payrolls, CPI loom

Dow Jones Industrial Average slips under 50,000 as AI shakeout bites; payrolls, CPI loom

The Dow Jones fell 133 points to 49,983 in Monday morning trade, slipping below 50,000 after Friday’s record close. The S&P 500 dipped 0.08% and the Nasdaq was flat as investors rotated out of tech and into industrial and defensive stocks. Amgen and Merck together shaved about 79 points from the Dow. Traders await key payrolls and inflation data later this week.
9 February 2026
···
Merck stock is inches from a 52-week high — and an insider just sold shares

Merck stock is inches from a 52-week high — and an insider just sold shares

Merck shares closed up 1.8% at $121.93 on Friday, marking a seventh straight gain and finishing just below a 52-week high. A regulatory filing showed Animal Health chief Richard R. DeLuca sold 37,685 shares on Feb. 6 at an average of $120.92. Trading volume was about 13 million shares, below the 50-day average. Investors await Monday trading after Merck’s 2026 outlook and pipeline updates.
8 February 2026
··
Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck shares rose about 2% to $120.72 Thursday after forecasting 2026 sales and profits below Wall Street estimates, citing patent expiries on older drugs. The company reported Q4 global sales of $16.4 billion and non-GAAP EPS of $2.04, and expects 2026 sales of $65.5–$67.0 billion. Health Canada approved ENFLONSIA for RSV prevention in infants. FDA review of WINREVAIR is set for September 21, 2026.
5 February 2026
··
Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck shares rose 2.2% to $118.33 in after-hours trading Wednesday after new data showed its experimental cholesterol drug enlicitide cut LDL by up to 60% in a major trial. The company’s 2026 revenue forecast of $65.5–$67.0 billion missed Wall Street estimates, citing pressure from off-patent drugs and U.S. pricing. Keytruda sales reached $8.37 billion last quarter, while Gardasil revenue fell 34%.
5 February 2026
···
Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck shares rose 2.8% to $119.11 by midday Wednesday after the company beat Q4 expectations, but projected 2026 revenue of $65.5–$67.0 billion, below analyst forecasts. Keytruda sales climbed 7% while Gardasil dropped 34% on weak China demand. The company cited a $2.5 billion hit from generic drugs and U.S. pricing pressure. Investors remain focused on Merck’s ability to offset declines in older products.
4 February 2026
··
1 2 3 … 8

Stock Market Today

  • Nvidia Expands Buyback Program by $80 Billion, Evaluated by Susquehanna Analyst
    May 21, 2026, 5:33 AM EDT. Nvidia has increased its share buyback plan by $80 billion, signaling a substantial return of capital to shareholders. Susquehanna senior analyst Chris Rolland assessed the company's recent earnings report, highlighting strong financial performance and shareholder value strategies. The expanded buyback reflects Nvidia's confidence in its growth outlook amid ongoing demand in the semiconductor market.

Latest articles

Nokia Stock Slips as Its Big AI Networking Bet Enters a Crowded Race

Nokia Stock Slips as Its Big AI Networking Bet Enters a Crowded Race

21 May 2026
Nokia shares fell 0.7% to 11.650 euros in Helsinki on Thursday, underperforming the OMX Helsinki 25 index, after the company opened a new AI Networking Innovation Lab in Sunnyvale, California. The stock had recently hit a 16-year high following strong first-quarter results and a surge in AI and cloud orders.
American Airlines Stock Rises as Oil Falls, Traders Track Fuel Prices

American Airlines Stock Rises as Oil Falls, Traders Track Fuel Prices

21 May 2026
American Airlines shares rose 7.4% to $12.95 Wednesday as falling oil prices boosted airline stocks ahead of Thursday’s U.S. market open. Trading volume hit 85.4 million shares, well above earlier in the week. Brent crude slid 3% to $108.31 a barrel, easing jet-fuel cost concerns that had led American to cut its 2026 profit outlook last month. Delta, United, and other carriers also gained sharply.
Rocket Lab Shares Slide Premarket On $3 Billion Sale Plan During SpaceX IPO Week

Rocket Lab Shares Slide Premarket On $3 Billion Sale Plan During SpaceX IPO Week

21 May 2026
Rocket Lab filed to sell up to $3 billion in common stock, sending shares down to $126.75 in premarket trading from Wednesday’s $134.28 close. The move comes as SpaceX filed for a public IPO, raising valuation pressure across the sector. Rocket Lab’s year-to-date gain stood near 92% before the late-Wednesday announcement. The company reported $200.3 million in Q1 revenue and a $2.2 billion backlog.
Go toTop